A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Methyldopa

First FDA approval1984-06-29
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$16,016 in CY2024 Part D spend43 claims · 28 beneficiaries · 329 plans surveyed

Lowest NADAC
$7.50/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$7.50
Across all dosage forms in distribution.
Highest NADAC
$7.50
Range is tight.
Plans with PA
10 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Methyldopa used for?

Methyldopa is a this drug class medication tracked in Medicare Part D.

Is there a generic for Methyldopa?

Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Methyldopa?

Across 329 Part D plans, Methyldopa averages $7.50/unit (NADAC). Lowest available: $7.50/unit. Highest in distribution: $7.50/unit.

Is Methyldopa on the FDA shortage list?

No. Methyldopa is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.